Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wyeth discontinues Suprax

Executive Summary

Wyeth will continue to sell oral antimicrobial Suprax (cefixime) suspension through March or until company's supply is depleted, following decision to discontinue the product. Cefixime lost patent protection on Nov. 10; Wyeth said it had always intended to cease marketing the drug once it lost exclusivity...

You may also be interested in...

Suprax returning to market

The cephalosporin antibiotic Suprax (cefixime) is returning to the market after a one-year absence. The Bombay-based generic drug firm Lupin is taking over the product from Wyeth, which discontinued production in 2002 (1"The Pink Sheet" Dec. 2, 2002, In Brief); stock was exhausted in 2003. Lupin expects to have the oral suspension formulation available in April following the approval of its ANDA (65-129) on Feb. 23. The company is not projecting availability for the tablets (ANDA 65-130), approved Feb. 12. Suprax will be Lupin's first U.S. product and will be detailed by 45 sales reps calling primarily on pediatricians. Sales of Suprax during Wyeth's last year of production were approximately $50 mil...

While Opening Dietary Ingredient Portfolio Wider, DuPont Opens Door On Online Supply Store

In its “robust, holistic hub” online, firms in the VMS product supply chain can determine their needs, “by product, solution or delivery formats,” and use a “comprehensive and unique portfolio” to “turn natural sources into shelf-ready products.”

Asia Deal Watch: Takeda, KSQ Take CRISPR Approach To T-Cell Oncology Therapy

Plus deals involving Astellas/Actinium, Sosei/PharmEnable, Aadi/EOC Pharma, BeiGene/Strand, Chi-Med/Inmagene, Alteogen/Intas, Sosei/AbbVie, Y-Biologics/3D Medicines.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts